Preparation, Characterization and in Vitro Anticancer Activity of Platinum(II) Complexes with N-Cyclohexyl-1,3-propanediamine as the Carrier

  • Liu Weiping
    Platinum-Based Drug Lab, Kunming Institute of Precious Metals
  • Qing Chen
    Kunming Medical College
  • Chen Xizhu
    Platinum-Based Drug Lab, Kunming Institute of Precious Metals
  • Ye Qingsong
    Platinum-Based Drug Lab, Kunming Institute of Precious Metals
  • Yu Yao
    Platinum-Based Drug Lab, Kunming Institute of Precious Metals
  • Hou Shuqian
    Platinum-Based Drug Lab, Kunming Institute of Precious Metals

Bibliographic Information

Other Title
  • Preparation, characterization and in vitro anticancer activity of platinum(2) complexes with N-cyclohexyl-1,3-propanediamine as the carrier

Search this article

Abstract

New JM118 (active form of satraplatin) analogues with N-cyclohexyl-1,3-propanediamine (N-chpda) as the carrier, cis-[Pt(N-chpda)X2] (X2=2Cl (1), oxalate (2), malonate (3), 1,1-cyclobutanedicarboxylate (CBDCA) (3), and 3-hydroxy-1,1-cyclobutanedicarboxylate(HO-CBDCA) (4)), have been synthesized and characterized by elemental analysis and spectroscopic data along with X-ray crystal structure for a representative compound cis-[Pt(N-chpda)Cl2].The complexes have also been evaluated for their in vitro anticancer activity. All these analytical data are in good agreement with the structures of the desired compounds. The Pt(II) is in a square planar environment and is coordinated by a chelating N-chpda ligand and 2Cl in cis position, and there are two crystallographically independent cis-[Pt(N-chpda)Cl2] molecules linked together by intermolecular N–H···Cl hydrogen bonds. Compounds 1 and 2 are very active against human lung cancer cell line (AGZY) and human lymphocytic leukemia cell line (Raji), and are much more active than carboplatin. Platinum(II) complexes with N-cyclohexyl-1,3-propanediamine is an alternative choice for mixed ammine/aminoplatinum anticancer drugs.

Journal

Citations (1)*help

See more

References(45)*help

See more

Details 詳細情報について

Report a problem

Back to top